

Entecavir

Catalog No: tcsc3160



Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

142217-69-4

Formula:

$C_{12}H_{15}N_5O_3$

Pathway:

Anti-infection

Target:

HBV

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 44 mg/mL (158.68 mM)

Alternative Names:

BMS200475;SQ34676

Observed Molecular Weight:

277.28


Product Description

Entecavir (SQ 34676; BMS 200475) is a potent and selective inhibitor of **HBV**, with an **EC₅₀** of 3.75 nM in HepG2 cell.

IC50 & Target: EC50: 3.75 nM (anti-HBV, HepG2 cell)^[2]

In Vitro: BMS-200475 has a EC₅₀ of 3.75 nM against HBV. It is incorporated into the protein primer of HBV and subsequently inhibits the priming step of the reverse transcriptase. The antiviral activity of BMS-200475 is significantly less against the other RNA and DNA viruses^[1]. Entecavir is more readily phosphorylated to its active metabolites than other deoxyguanosine analogs (penciclovir, ganciclovir, lobucavir, and aciclovir) or lamivudine. The intracellular half-life of entecavir is 15 h^[2].

In Vivo: Daily oral treatment with BMS-200475 at doses ranging from 0.02 to 0.5 mg/kg of body weight for 1 to 3 months effectively reduces the level of woodchuck hepatitis virus (WHV) viremia in chronically infected woodchucks^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!